Cybin Inc.
CYBN | AMEX
$8.28
$0.00 (0.00%)
Nov 2, 2026, 10:34 AM ET · Market open
Company Profile
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
Key Executives
| Name | Position |
|---|---|
| Eric So | Co-Founder, Interim Chief Executive Officer, President & Executive Chairman |
| Aaron Bartlone | Chief Operating Officer |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| Greg Cavers | Chief Financial Officer |
| Alex L. Nivorozhkin | Chief Scientific Officer |
| George Tziras | Chief Business Officer |
| John Kanakis | Co-Founder |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Sara Brittany Somerset | Chief Communications Officers |
Cybin Inc.
| Country | Canada |
| IPO Date | Sep 13, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Eric So |
Stock Details
| Ticker Symbol | CYBN |
| Exchange | AMEX |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001833141 |
| CUSIP Number | 23256X407 |
| ISIN Number | CA23256X4075 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CYBN